Exact Sciences generated $99.4 million in revenues during 2016, a 152-percent increase

 

Cologuard gross margin reached 61 percent in fourth quarter

MADISON, Wis., Feb. 21, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $99.4 million and completed approximately 244,000 Cologuard tests during the year ended Dec. 31, 2016. Full-year 2016 revenues and Cologuard test volume grew 152 percent and 135 percent from 2015, respectively.

Read More

CMS Proposes Inclusion of Cologuard in Medicare Advantage Star Ratings

 

Cologuard offers health plans an opportunity to increase screening & improve quality ratings

MADISON, Wis., Feb. 2, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is included in the Medicare Advantage Advance Notice and Draft Call letter.  Cologuard's inclusion in the final Star Ratings will allow Medicare Advantage plans to increase their Star Rating when patients complete Exact Sciences' non-invasive colon cancer screening test.

Read More